Healthtech Series C Investors & VC Firms
564 firms in this list, with a median first check of $1M. 141 of them lead rounds. Generated from verified public data and updated continuously.
McKesson Ventures
San FranciscoSeed–Growth
17 people
Jerusalem Venture Partners (JVP)
JerusalemSeed–Growth$1M – $5M
24 people
Princeville Capital
San FranciscoSeries A–Late Stage
28 people
Founders Future
ParisPre-Seed–Growth
15 people
AllianceBernstein
NashvillePre-Seed–Late Stage
37 people
IDG Capital
Hong KongPre-Seed–Late Stage$1M – $100M
8 people
Zeno Ventures
GenevaPre-Seed–Series C
4 people
SC Ventures
SingaporeSeed–Growth
21 people
Catalyst Investors
New YorkSeries A–Growth$10M – $20M
20 people
Softbank Latin America Fund
MiamiSeed–Growth
11 people
Fifth Down Capital
DoverSeed–Late Stage
25 people
Hiroshima Venture Capital Co. Ltd.
HiroshimaPre-Seed–Growth
11 people
Georgian
Toronto, OntarioSeries C–Growth$25M – $100M
18 people
Sampac Tech Fund
Palo AltoSeed–Late Stage
31 people
SBVA
SeoulSeed–Growth$1M – $2.5M
12 people
Lightrock
LondonSeries A–Growth
21 people
Third Point Ventures
Menlo ParkSeed–Late Stage
6 people
UKSE
SheffieldSeries A–Late Stage
34 people
QVentures
LondonPre-Seed–Growth$127K – $6.3M
5 people
Lilly Asia Ventures
Hong KongPre-Seed–Series C
3 people
Remgro / Invenfin ecosystem
StellenboschSeed–Growth
21 people
Windham Capital Partners
New YorkSeries A–Growth$1M – $5M
17 people
TCG Crossover
Palo AltoSeed–Late Stage
25 people
PLUS Capital
VeniceSeed–Growth$100K – $1M
14 people
Related lists
Healthtech Investors & VC Firms (4227)Healthtech Seed Investors & VC Firms (3260)Healthtech Investors & VC Firms in North America (2705)Healthtech Investors & VC Firms in United States (2474)Healthtech Series A Investors & VC Firms (2328)Series C Investors & VC Firms (1709)Healthtech Pre-Seed Investors & VC Firms (1491)Healthtech Investors & VC Firms in Europe (1370)Healthtech Growth Investors & VC Firms (1282)Healthtech Investors & VC Firms in Global (1200)
Data sourced from public filings and firms' own websites — see our methodology.
































































































